

4 December 2025

Companies Announcements Office
Australian Securities Exchange

Positive momentum in US reimbursement coverage continues

ImpediMed Limited (ASX: IPD) (**ImpediMed** or the **Company**) is pleased to announce a further three U.S. state-based insurers and one multi-state insurer have initiated coverage for CPT Code 93702, recognising bioimpedance spectroscopy (BIS) as medically necessary for the assessment of lymphoedema. This further supports reimbursement for lymphoedema testing using ImpediMed's SOZO® Digital Health Platform and represents another positive step forward in our mission to prevent breast cancer-related lymphoedema.

The announcement adds to the recent momentum in insurance coverage, representing an additional 60 million covered lives this financial year and bringing total reimbursed coverage for lymphoedema testing using ImpediMed's SOZO Digital Health Platform SOZO to over 314 million covered lives and over 90% total coverage nationwide. Two of the states are top 10 states by population and all insurers have meaningful number of covered lives in their states. The salient points are as follows:

- 10.5 million additional covered lives
- Total covered lives increased from 304 million to 314.5 million
- National total lives covered now at 90.3%
- 60 million covered lives added this financial year
- Number of states over 80%: Increased from 42 to 45
- Number of states over 90%: Increased from 27 to 32
- Number of states over 95%: Increased from 14 to 18
- Two insurers are in top 10 states by population
- 6 of the top 10 states in population are over 90% coverage
- All top 10 states in population are over 80% coverage.

This is a positive development for breast cancer survivors across the United States. This additional insurance coverage for lymphoedema assessment using bioimpedance spectroscopy (BIS), means more than 90% of all US patients are now reimbursed for their treatment. This expanded access means that millions of patients can benefit from earlier detection and more accurate monitoring of lymphoedema—one of the most common and debilitating side effects following breast cancer treatment. Early identification through BIS allows for timely intervention, helping to prevent progression to more severe stages of lymphoedema, reduce long-term complications, and improve overall quality of life. For survivors, this coverage expansion represents not just broader access to care, but a meaningful step toward proactive, preventative health management and peace of mind during recovery.

Dr Parmjot Bains Managing Director of ImpediMed said:

"More than ever, having a fully reimbursed product is necessary and decisions from major insurance companies to recognise the medical necessity of using bioimpedance spectroscopy (BIS) for lymphoedema assessment is pivotal to enhance the commercial feasibility of implementing a SOZO-based lymphoedema prevention program. This is a tough year for US healthcare systems with an estimated 8.5% healthcare cost inflation¹ and policy changes which McKinsey estimates which could cause margin pressures of 2 to 13 percentage points for health systems². Hospitals are often being forced to prioritise budget discipline, even when the clinical benefits for patients are evident.

"We remain committed to investing the resources needed to expand our business and increase SOZO adoption, enabling more patients to benefit from early detection and proactive care. We expect the recent momentum in coverage to have a meaningful effect for commercialisation of SOZO. With these recent changes we are making steady progress toward our goal: ensuring that all cancer patients at risk of lymphoedema have access to prospective surveillance through SOZO."

Approved for release by the CEO of ImpediMed Limited.

For more information, contact ImpediMed Investor Relations at investorrelations@impedimed.com

For personal use only

¹ <https://www.pwc.com/us/en/industries/health-industries/library/behind-the-numbers.html>

² <https://www.beckershospitalreview.com/finance/4-forces-confronting-health-systems-in-2025-mckinsey/>

About ImpediMed

Founded in Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health. ImpediMed produces the SOZO® Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally.

With the SOZO Digital Health Platform and L-Dex®, ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital health platform and large, attractive cancer-related lymphoedema market present an opportunity for continued strong growth through ImpediMed's SaaS subscription-based business.

For more information, visit www.impedimed.com.

Forward looking statements

This announcement contains or may contain forward-looking statements that are based on ImpediMed management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. Any forward-looking statements, including projections, guidance on future revenues, earnings and estimates, are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

While management has prepared this information based on its current knowledge and understanding and in good faith, there are risks and uncertainties involved which could cause actual results to differ from projections. You should not place undue reliance on forward-looking statements which speak only as of the date when made. Except as required by law, ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements and no representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including ImpediMed Limited).